Clinical trial
Cladribine and Rituximab as Remission Induction Therapy Followed By Rituximab…
NCT00072007 · Swiss Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00072007 |
|---|---|
| Title | Cladribine and Rituximab as Remission Induction Therapy Followed By Rituximab and Stem Cell Mobilization in Treating Patients With CLL |
| Official title | 2-CDA and Rituximab as Remission Induction and Rituximab as In Vivo Purging Prior to Peripheral Stem Cell Mobilization in Patients With Chronic Lymphocytic Leukemia (CLL) - A Prospective Multicenter Phase II Trial |
| Lead sponsor | Swiss Cancer Institute, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Biological, Drug |
| Interventions | filgrastim, rituximab, CHOP regimen, cladribine, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate |
| Enrollment | 43 |
| Start date | Jun 1, 2002 |
| Primary completion | Mar 1, 2003 |
| Completion | Oct 1, 2010 |
| First posted | Nov 6, 2003 |
| Last update posted | May 15, 2012 |
| Countries | Switzerland |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: